menu ☰
menu ˟

TKI cessation feasible for patients with CML in deep molecular remission

05 Dec 2016
SAN DIEGO — Patients with chronic myeloid leukemia with a deep molecular response were safely able to stop tyrosine kinase inhibitor therapy with high rates of molecular recurrence–free survival, according to results of the EURO-SKI trial present...

Click here to view the full article which appeared in Hematology Oncology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.